Summary
Mitoquidone (MTQ) is the first member of a new group of pentacyclic pyrroloquinones developed for clinical evaluation as a potential anticancer agent. MTQ demonstrated good activity in a range of experimental solid tumour models, but was weakly active against standard prescreens such as the P388 murine leukaemia. Bone marrow suppression or other significant toxicity was not observed in preclinical studies. Twenty-seven patients were treated with MTQ given as a 4-h infusion either once every 21 days (150–600 mg/m2), once a week (200 mg/m2 per week), or as 5 daily doses repeated every 28 days (60–180 mg/m2 per day). The major adverse events encountered included nausea and vomiting (in virtually all patients), dyspnoea, tumour-related pain, and thrombocytopenia in several patients with pretreatment bone-marrow impairment. Phase I studies were suspended without a maximum tolerated dose being reached because of formulation difficulties. There were no major responses, although stable disease was observed in a number of patients with gastrointestinal malignancies. Temporary remission of B-symptoms occurred in two patients with lymphoma. The plasma pharmacokinetics of MTQ were investigated using an HPLC assay with fluorescence detection. Linear pharmacokinetics were observed with a terminal plasma half-life of 2.9±2.1 h (n=18 doses). The volume of distribution was 3.4±2.6 l/kg and plasma clearance was 629±469 ml/min per m2. Several soluble analogues with similar antitumour activity are currently under investigation.
Similar content being viewed by others
References
Collins JM, Zaharko DS, Dedrick RL, Chabner BA (1986) Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 70:73
Fenton R, Kumar A, Spilling C, Elves M (1985) Studies with GR30921 (NSC 382057D), a new antitumour pyrroloquinone, in animal tumour models. Anticancer Res 5:592
Kelner MJ, Bailey DN (1985) Propylene glycol as a cause of lactic acidosis. J Anal Toxicol 9:40
Metzler CM, Elfring GL, McEwan AJ (1974) A users' manual for NONLIN and associated programs. Upjohn, Kalamazoo
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207
Scott RB, Tisdale BA, Cummings WB (1977) Hemolytical potential of methocarbamol. Clin Pharmacol Ther 21:208
Author information
Authors and Affiliations
Additional information
This work was supported by Glaxo Group Research Ltd., Greenford, UK
Rights and permissions
About this article
Cite this article
Speth, P.A.J., Gore, M.E., Pateman, A.J. et al. Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitoquidone. Cancer Chemother. Pharmacol. 21, 343–346 (1988). https://doi.org/10.1007/BF00264202
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00264202